Alma Osmanovic
Overview
Explore the profile of Alma Osmanovic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
723
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Meyer T, Maier A, Uzelac Z, Hagenacker T, GuNTHER R, Schreiber-Katz O, et al.
Eur J Neurol
. 2021 May;
28(8):2582-2595.
PMID: 33960080
Background And Purpose: This was an investigation of treatment expectations and of the perception of therapy in adult patients with 5q-associated spinal muscular atrophy (5q-SMA) receiving nusinersen. Methods: A prospective,...
22.
Osmanovic A, Schreiber-Katz O, Petri S
Brain Sci
. 2021 Apr;
11(3).
PMID: 33805645
The antisense oligonucleotide nusinersen was the first drug treatment available for all types of 5q-spinal muscular atrophy (SMA). The dosing regime has been derived from pivotal clinical trials in infants...
23.
Peseschkian T, Cordts I, GuNTHER R, Stolte B, Zeller D, Schroter C, et al.
Brain Sci
. 2021 Apr;
11(3).
PMID: 33799476
Improving quality of life (QoL) is central to amyotrophic lateral sclerosis (ALS) treatment. This Germany-wide, multicenter cross-sectional study analyses the impact of different symptom-specific treatments and ALS variants on QoL....
24.
Freigang M, Wurster C, Hagenacker T, Stolte B, Weiler M, Kamm C, et al.
Ann Clin Transl Neurol
. 2021 Apr;
8(5):1049-1063.
PMID: 33792208
Objective: To determine whether serum creatine kinase activity (CK) and serum creatinine concentration (Crn) are prognostic and predictive biomarkers for disease severity, disease progression, and nusinersen treatment effects in adult...
25.
Osmanovic A, Ranxha G, Kumpe M, Wurster C, Stolte B, Cordts I, et al.
Ther Adv Neurol Disord
. 2021 Mar;
14:1756286421998902.
PMID: 33747131
Background: Nusinersen was the first approved disease-modifying therapy for all 5q-spinal muscular atrophy (SMA) patients regardless of age or disease severity. Its efficacy in adults has recently been demonstrated in...
26.
Hendrik Muschen L, Osmanovic A, Binz C, Jendretzky K, Ranxha G, Bronzlik P, et al.
Brain Sci
. 2021 Mar;
11(3).
PMID: 33652830
Approval of nusinersen, an intrathecally administered antisense oligonucleotide, for the treatment of 5q-spinal muscular atrophy (SMA) marked the beginning of a new therapeutic era in neurological diseases. Changes in routine...
27.
Mix L, Schreiber-Katz O, Wurster C, Uzelac Z, Platen S, Gipperich C, et al.
Orphanet J Rare Dis
. 2021 Jan;
16(1):10.
PMID: 33407722
Background: Spinal muscular atrophy (SMA) issues from mutations in the survival of motor neuron (SMN) 1 gene. Loss or reduction of the SMN protein results in progressive muscle weakness. Whether...
28.
Osmanovic A, Wieselmann G, Mix L, Siegler H, Kumpe M, Ranxha G, et al.
Brain Sci
. 2020 Dec;
11(1).
PMID: 33374658
Motor neuron diseases, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), share several clinical similarities while differing substantially in etiology, disease onset and progression. Cognitive dysfunction, a...
29.
Binz C, Schreiber-Katz O, Kumpe M, Ranxha G, Siegler H, Wieselmann G, et al.
J Neurol
. 2020 Oct;
268(3):950-962.
PMID: 33029682
Background: Efficacy of nusinersen in adult 5q-spinal muscular atrophy (SMA) patients regarding motor function has recently been demonstrated. However, additional outcome measures are needed to capture non-motor improvements. Fatigue is...
30.
Schonfelder E, Osmanovic A, Hendrik Muschen L, Petri S, Schreiber-Katz O
Orphanet J Rare Dis
. 2020 Jun;
15(1):149.
PMID: 32532288
Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder. Consequently, patients undergo a multidisciplinary treatment that often requires intensive use of medical resources. This study provides an estimate on...